Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IGMS IGM Biosciences	$1.30 +0.8%	$1.27	$0.92 ▼ $22.50	$77.78M	0.6	506,553 shs	351,837 shs
JMAC Maxpro Capital Acquisition	$5.69 +0.3%	$6.18	$7.50 ▼ $19.22	$76.41M	0.01	74,040 shs	54,241 shs
MBRX Moleculin Biotech	$0.66 +6.4%	$0.58	$0.25 ▼ $3.65	$18.79M	1.39	3.50 million shs	546,146 shs
MGX Metagenomi	$1.88 +2.7%	$1.88	$1.23 ▼ $4.92	$68.41M	-0.12	659,561 shs	420,087 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IGMS IGM Biosciences	+1.57%	-0.77%	-5.15%	+12.17%	-85.03%
JMAC Maxpro Capital Acquisition	0.00%	-3.32%	+4.13%	+10.47%	+3,427.04%
MBRX Moleculin Biotech	-7.78%	-9.30%	+13.07%	-41.87%	-72.48%
MGX Metagenomi	-4.69%	-20.43%	-16.06%	+14.38%	-36.46%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IGMS IGM Biosciences	4.3478 of 5 stars	3.0	3.0	0.0	4.6	3.1	3.3	0.6
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MBRX Moleculin Biotech	2.6808 of 5 stars	3.5	2.0	0.0	0.0	2.2	1.7	1.3
MGX Metagenomi	3.008 of 5 stars	3.5	4.0	0.0	0.0	2.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IGMS IGM Biosciences	1.90	Reduce	$5.50	323.08% Upside
JMAC Maxpro Capital Acquisition	0.00	N/A	N/A	N/A
MBRX Moleculin Biotech	3.00	Buy	$4.00	504.14% Upside
MGX Metagenomi	3.00	Buy	$13.00	591.49% Upside

Current Analyst Ratings Breakdown

Latest MBRX, JMAC, MGX, and IGMS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	MBRX Moleculin Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
6/9/2025	MBRX Moleculin Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$4.00
5/15/2025	MGX Metagenomi	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$13.00 ➝ $12.00
5/14/2025	MGX Metagenomi	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$20.00 ➝ $16.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IGMS IGM Biosciences	$2.68M	29.25	N/A	N/A	$1.67 per share	0.78
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	$1.77 per share	N/A
MGX Metagenomi	$52.29M	1.34	N/A	N/A	$6.28 per share	0.30

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IGMS IGM Biosciences	-$195.79M	-$0.90	N/A	N/A	N/A	-36.81%	-93.35%	-24.15%	8/13/2025 (Estimated)
JMAC Maxpro Capital Acquisition	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
MBRX Moleculin Biotech	-$21.76M	N/A	0.00	N/A	N/A	N/A	-278.80%	-100.11%	8/12/2025 (Estimated)
MGX Metagenomi	-$78.06M	-$2.11	N/A	N/A	N/A	-172.21%	-31.21%	-22.21%	8/13/2025 (Estimated)

Latest MBRX, JMAC, MGX, and IGMS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	IGMS IGM Biosciences	-$0.12	N/A	N/A	N/A	$0.40 million	N/A
8/12/2025	Q2 2025	MBRX Moleculin Biotech	-$0.42	-$0.49	-$0.07	-$0.49	N/A	N/A
8/12/2025	Q2 2025	MGX Metagenomi	-$0.62	-$0.54	+$0.08	-$0.54	$7.72 million	N/A
7/31/2025	Q2 2025	IGMS IGM Biosciences	-$0.30	$1.58	+$1.88	$1.58	$3.20 million	$143.62 million
5/13/2025	Q1 2025	IGMS IGM Biosciences	-$0.41	-$0.86	-$0.45	-$0.86	$4.25 million	$0.50 million
5/13/2025	Q1 2025	MBRX Moleculin Biotech	-$0.71	-$0.69	+$0.02	-$0.69	N/A	N/A
5/13/2025	Q1 2025	MGX Metagenomi	-$0.62	-$0.68	-$0.06	-$0.68	$8.75 million	$4.13 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IGMS IGM Biosciences	N/A	N/A	N/A	N/A	N/A
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	N/A
MGX Metagenomi	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IGMS IGM Biosciences	N/A	17.66	17.66
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A
MBRX Moleculin Biotech	N/A	1.35	1.35
MGX Metagenomi	N/A	5.85	5.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IGMS IGM Biosciences	42.79%
JMAC Maxpro Capital Acquisition	73.18%
MBRX Moleculin Biotech	15.52%
MGX Metagenomi	N/A

Insider Ownership

Company	Insider Ownership
IGMS IGM Biosciences	57.00%
JMAC Maxpro Capital Acquisition	19.27%
MBRX Moleculin Biotech	2.10%
MGX Metagenomi	17.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IGMS IGM Biosciences	190	60.29 million	25.93 million	Optionable
JMAC Maxpro Capital Acquisition	2,021	13.43 million	10.84 million	Not Optionable
MBRX Moleculin Biotech	20	30.21 million	29.57 million	Not Optionable
MGX Metagenomi	236	37.38 million	30.73 million	N/A

MBRX, JMAC, MGX, and IGMS Headlines

Recent News About These Companies

Metagenomi: Q2 Earnings Snapshot

1 hour ago | timesunion.comT

Metagenomi Reports Strong Q2 2025 Financial Results

1 hour ago | msn.com

Metagenomi (MGX) Reports Q2 Loss, Tops Revenue Estimates

4 hours ago | zacks.com

Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results

August 12 at 4:05 PM | globenewswire.com

Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

August 11 at 4:05 PM | globenewswire.com

Metagenomi (MGX) to Release Quarterly Earnings on Wednesday

August 7, 2025 | marketbeat.com

Metagenomi (MGX) Presents Latest in Gene Editing Technologies

July 29, 2025 | msn.com

Metagenomi Showcases Advanced AI-Enhanced Gene Editing for Neurological Disorders at ASGCT Meeting

July 14, 2025 | msn.com

Insider Selling: Metagenomi, Inc. (NASDAQ:MGX) CEO Sells 10,785 Shares of Stock

June 10, 2025 | insidertrades.com

Metagenomi, Inc. (NASDAQ:MGX) Analysts Are Cutting Their Estimates: Here's What You Need To Know

May 16, 2025 | finance.yahoo.com

2MGX : Demystifying Metagenomi: Insights From 4 Analyst Reviews

May 15, 2025 | benzinga.com

Metagenomi Reports Promising Hemophilia A Study Results

May 14, 2025 | tipranks.com

Metagenomi, Inc.: Metagenomi Reports Business Updates and First Quarter 2025 Financial Results

May 14, 2025 | finanznachrichten.de

Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025

May 14, 2025 | globenewswire.com

Metagenomi (MGX) Reports Q1 Loss, Misses Revenue Estimates

May 13, 2025 | zacks.com

Metagenomi Reports Business Updates and First Quarter 2025 Financial Results

May 13, 2025 | globenewswire.com

Metagenomi to Present at Upcoming Scientific Meetings

May 2, 2025 | globenewswire.com

Metagenomi Leads The Charge With These 3 Penny Stocks

April 10, 2025 | uk.finance.yahoo.com

Metagenomi price target lowered to $7 from $14 at H.C. Wainwright

April 4, 2025 | markets.businessinsider.com

Metagenomi, Inc. Common Stock (MGX) Latest After Hours Trades

March 31, 2025 | nasdaq.com

Biotech stocks slide as Marks resignation seen being negative for sector

March 31, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBRX, JMAC, MGX, and IGMS Company Descriptions

IGM Biosciences NASDAQ:IGMS

$1.30 +0.01 (+0.78%)

Closing price 04:00 PM Eastern

Extended Trading

$1.30 0.00 (0.00%)

As of 07:21 PM Eastern

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Maxpro Capital Acquisition NASDAQ:JMAC

$5.69 +0.02 (+0.26%)

As of 08/11/2025

Maxpro Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Taipei City, Taiwan.

Moleculin Biotech NASDAQ:MBRX

$0.66 +0.04 (+6.45%)

Closing price 04:00 PM Eastern

Extended Trading

$0.64 -0.02 (-3.49%)

As of 07:58 PM Eastern

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Metagenomi NASDAQ:MGX

$1.88 +0.05 (+2.73%)

Closing price 04:00 PM Eastern

Extended Trading

$1.85 -0.03 (-1.60%)

As of 07:59 PM Eastern

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time